BridgeBio monetizes EU acoramidis royalties for $300M cash; caps future payments

BridgeBio Pharma, Inc.

Eidos sold right to receive certain royalties on acoramidis net sales in EU and EPO states to ARS and LSI Financing Fund.
Purchase price of $300M paid in full at closing on June 27, 2025.
Purchaser's annual cap equals 60% of Bayer royalties on first $500M of net sales; hard cap at 145% of purchase price.
Company granted security interest in assets related to purchased royalty payment; change of control triggers option to assume or pay adjusted amount.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.